Drug Type Fusion protein |
Synonyms ACTRIIB-IGG1, ActRIIb:Fc Fusion Protein, Ramatercept (USAN) + [3] |
Target |
Mechanism MSTN inhibitors(Growth/differentiation factor 8 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Muscular Dystrophies | Phase 2 | GB | 09 Sep 2010 | |
Muscular Dystrophy, Duchenne | Phase 2 | CA | 01 Apr 2010 | |
Muscular Atrophy | Phase 1 | CA | 01 Sep 2008 | |
Osteogenesis Imperfecta | Preclinical | US | - |
NCT01099761 (Pubmed) Manual | Phase 2 | - | zhtjofxtnz(pbuhbagnqe) = A trend for maintenance of the 6-minute walk test (6MWT) distance in the ACE-031 groups compared with a decline in the placebo group (not statistically significant) was noted hlhduijfuf (fxxsymaswz ) | Negative | 01 Apr 2017 | ||
Placebo | |||||||
Phase 2 | 24 | (ACE-031 0.5 mg/kg q4wk) | twbrnchidw(lpfmxvmtuz) = gpvdcpagin xpvtdztzqt (exmfwiosbh, cvamdlrfla - mgkzfysgcr) View more | - | 14 Oct 2016 | ||
(ACE-031 1.0 mg/kg q2wk) | twbrnchidw(lpfmxvmtuz) = wlcwpbreyt xpvtdztzqt (exmfwiosbh, lmyrvpoacz - xovwwelquk) View more | ||||||
Phase 2 | - | rtaexlnuhk(atzshhroxy) = reported at higher dose tgdzpukxsf (wdnqpxqppm ) View more | Positive | 23 Apr 2012 | |||
Placebo |